|
WO2021011227A1
|
|
Infusion system
|
|
TW202039583A
|
|
Proteinaceous molecules binding factor ixa and factor x
|
|
WO2020115283A1
|
|
Bispecific antibodies binding factor ixa and factor x
|
|
WO2020072231A1
|
|
Packaging for multiple containers
|
|
WO2020072234A1
|
|
Detection assemblies for infusion pumps
|
|
EP3806973A1
|
|
Bottom section for being connected to an assembly with plate settler, and assembly with plate settler
|
|
BR112020013197A2
|
|
purification methods of adenoassociated viruses
|
|
WO2020114615A1
|
|
Bispecific antibodies binding factor ixa and factor x
|
|
WO2020114614A1
|
|
Proteinaceous molecules binding factor ixa and factor x
|
|
BR112020008414A2
|
|
environmentally compatible detergents for inactivating viruses wrapped in lipids
|
|
JP2018115170A
|
|
Factor fviii-polymer conjugates
|
|
AU2017391164A1
|
|
Adeno-associated virus purification methods
|
|
WO2016184886A1
|
|
Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
|
|
EP3277718A1
|
|
Dosage regimen for anti-mif antibodies
|
|
AU2015275284A1
|
|
Nucleophilic Catalysts for Oxime Linkage
|
|
AU2015268579A1
|
|
Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
|
|
AU2015258348A1
|
|
Lyophilized Recombinant VWF Formulations
|
|
AU2015249186A1
|
|
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutal ph
|
|
AU2015234306A1
|
|
Tfpi inhibitors and methods of use
|
|
US2018215807A1
|
|
Detection of CHO-MIF contaminations
|
